Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 3, 2008, Pages 1121-1126

  Kokkotou, Efi ^a   Moss, Alan C ^a   Michos, Athanasios ^a   Espinoza, Daniel ^a   Cloud, Jeffrey W ^a   Mustafa, Nasima ^a   O'Brien, Michael ^b   Pothoulakis, Charalabos ^a   Kelly, Ciarán P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; RIFAXIMIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CLOSTRIDIUM DIFFICILE; COLITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FOLLOW UP; HAMSTER; HISTOLOGY; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; WEIGHT GAIN;

ANIMALS; ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CRICETINAE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; MESOCRICETUS; RIFAMYCINS; TREATMENT OUTCOME; VANCOMYCIN; WEIGHT GAIN;

EID: 40549090894     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01143-07     Document Type: Article

References (39)

1. Al-Eidan, F. A., J. C. McElnay, M. G. Scott, and M. P. Kearney. 2000. Clostridium difficile-associated diarrhoea in hospitalised patients. J. Clin. Pharm. Ther. 25:101-109.
2. Anton, P. M., M. O'Brien, E. Kokkotou, B. Eisenstein, A. Michaelis, D. Rothstein, S. Paraschos, C. P. Kelly, and C. Pothoulakis. 2004. Rifalazil treats and prevents relapse of Clostridium difficile-associated diarrhea in hamsters. Antimicrob. Agents Chemother. 48:3975-3979.
3. Aslam, S., R. J. Hamill, and D. M. Musher. 2005. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis. 5:549-557.
4. Barbut, F., and J. C. Petit. 2001. Epidemiology of Clostridium difficile-associated infections. Clin. Microbiol. Infect. 7:405-410.
5. Bartlett, J. G. 2006. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann. Intern. Med. 145:758-764.
6. Bartlett, J. G., N. Moon, T. W. Chang, N. Taylor, and A. B. Onderdonk. 1978. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 75:778-782.
7. Brigidi, P., E. Swennen, F. Rizzello, M. Bozzolasco, and D. Matteuzzi. 2002. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J. Chemother. 14:290-295.
8. Cellai, L., M. Colosimo, E. Marchi, A. P. Venturini, and G. Zanolo. 1984. Rifaximin (L/105), a new topical intestinal antibiotic: pharmacokinetic study after single oral administration of 3H-rifaximin to rats. Chemioterapia 3:373-377.
9. Chang, T. W., J. G. Bartlett, S. L. Gorbach, and A. B. Onderdonk. 1978. Clindamycin-induccd enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect. Immun. 20:526-529.
10. DuPont, H. L., Z. D. Jiang, P. C. Okhuysen, C. D. Ericsson, F. J. de la Cabada, S. Ke, M. W. DuPont, and F. Martinez-Sandoval. 2005. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann. Intern. Med. 142:805-812.
11. Gionchetti, P., F. Rizzello, A. Venturi, F. Ugolini, M. Rossi, P. Brigidi, R. Johansson, A. Ferrieri, G. Poggioli, and M. Campieri. 1999. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment. Pharmacol. Ther. 13:713-718.
12. Hecht, D. W., M. A. Galang, S. P. Sambol, J. R. Osmolski, S. Johnson, and D. N. Gerding. 2007. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob. Agents Chemother. 51:2716-2719.
13. Johnson, S., C. Schriever, M. Galang, C. P. Kelly, and D. N. Gerding. 2007. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. Dis. 44:846-848.
14. Kelly, C. P., S. Becker, J. K. Linevsky, M. A. Joshi, J. C. O'Keane, B. F. Dickey, J. T. LaMont, and C. Pothoulakis. 1994. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J. Clin. Investig. 93:1257-1265.
15. Kelly, C. P., C. Pothoulakis, and J. T. LaMont. 1994. Clostridium difficile colitis. N. Engl. J. Med. 330:257-262.
16. Kyne, L., R. J. Farrell, and C. P. Kelly. 2001. Clostridium difficile. Gastroenterol. Clin. N. Am. 30:753-777.
17. Kyne, L., M. Warny, A. Qamar, and C. P. Kelly. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189-193.
18. Loo, V. G., L. Poirier, M. A. Miller, M. Oughton, M. D. Libman, S. Michaud, A. M. Bourgault, T. Nguyen, C. Frenette, M. Kelly, A. Vibien, P. Brassard, S. Fenn, K. Dewar, T. J. Hudson, R. Horn, P. Rene, Y. Monczak, and A. Dascal. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353:2442-2449.
19. Marchese, A., A. Salerno, A. Pesce, E. A. Debbia, and G. C. Schito. 2000. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 46:253-266.
20. Maroo, S., and J. T. Lamont. 2006. Recurrent Clostridium difficile. Gastroenterology 130:1311-1316.
21. McDonald, L. C., G. E. Killgore, A. Thompson, R. C. Owens, Jr., S. V. Kazakova, S. P. Sambol, S. Johnson, and D. N. Gerding. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441.
22. McFarland, L. V., G. W. Elmer, and C. M. Surawicz. 2002. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am. J. Gastroenterol. 97:1769-1775.
23. McVay, C. S., and R. D. Rolfe. 2000. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob. Agents Chemother. 44:2254-2258.
24. Morris, A. M., B. A. Jobe, M. Stoney, B. C. Sheppard, C. W. Deveney, and K. E. Deveney. 2002. Clostridium difficile colitis: an increasingly aggressive iatrogenic disease? Arch. Surg. 137:1096-1100.
25. Musher, D. M., S. Aslam, N. Logan, S. Nallacheru, I. Bhaila, F. Borchert, and R. J. Hamill. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40:1586-1590.
26. O'Brien, J. A., B. J. Lahue, J. J. Caro, and D. M. Davidson. 2007. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect. Control Hosp. Epidemiol. 28:1219-1227.
27. Olson, M. M., C. J. Shanholtzer, J. T. Lee, Jr., and D. N. Gerding. 1994. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect. Control Hosp. Epidemiol. 15:371-381.
28. Pelaez, T., L. Alcala, R. Alonso, M. Rodriguez-Creixems, J. M. Garcia-Lechuz, and E. Bouza. 2002. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob. Agents Chemother. 46:1647-1650.
29. Pepin, J., M. E. Alary, L. Valiquette, E. Raiche, J. Ruel, K. Fulop, D. Godin, and C. Bourassa. 2005. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis. 40:1591-1597.
30. Pepin, J., L. Valiquette, M. E. Alary, P. Villemure, A. Pelletier, K. Forget, K. Pepin, and D. Chouinard. 2004. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can. Med. Assoc. J. 171:466-472.
31. Pindera, L. 2004. Quebec to report on Clostridium difficile in 2005. Can. Med. Assoc. J. 171:715.
32. Prantera, C., H. Lochs, M. Campieri, M. L. Scribano, G. C. Sturniolo, F. Castiglione, and M. Cottone. 2006. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment. Pharmacol. Ther. 23:1117-1125.
33. Rupnik, M., B. Dupuy, N. F. Fairweather, D. N. Gerding, S. Johnson, I. Just, D. M. Lyerly, M. R. Popoff, J. I. Rood, A. L. Sonenshein, M. Thelestam, B. W. Wren, T. D. Wilkins, and C. von Eichel-Streiber. 2005. Revised nomenclature of Clostridium difficile toxins and associated genes. J. Med. Microbiol. 54:113-117.
34. Savidge, T. C., W. H. Pan, P. Newman, M. O'Brien, P. M. Anton, and C. Pothoulakis. 2003. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 125:413-420.
35. Tal, S., A. Gurevich, V. Guller, I. Gurevich, D. Berger, and S. Levi. 2002. Risk factors for recurrence of Clostridium difficile-associated diarrhea in the elderly. Scand. J. Infect. Dis. 34:594-597.
36. Taylor, D. N., R. McKenzie, A. Durbin, C. Carpenter, C. B. Atzinger, R. Haake, and A. L. Bourgeois. 2006. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin. Infect. Dis. 42:1283-1288.
37. Tyrrell, K. L., D. M. Citron, Y. A. Warren, H. T. Fernandez, C. V. Merriam, and E. J. Goldstein. 2006. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. Antimicrob. Agents Chemother. 50:2728-2731.
38. Wilcox, M. H., W. N. Fawley, C. D. Settle, and A. Davidson. 1998. Recurrence of symptoms in Clostridium difficile infection - relapse or reinfection? J. Hosp. Infect. 38:93-100.
39. Young, G. P., P. B. Ward, N. Bayley, D. Gordon, G. Higgins, J. A. Trapani, M. I. McDonald, J. Labrooy, and R. Hecker. 1985. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 89:1038-1045.